TRIB (Trinity Biotech) PE Ratio: At Loss (As of Jun. 25, 2026)


TRIB Trinity Biotech PLC TRIB
20 GF Score
Price $0.35
GF Value $0.73
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-25), Trinity Biotech's share price is $0.349. Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00. Therefore, Trinity Biotech's PE Ratio for today is At Loss.

During the past 13 years, Trinity Biotech's highest PE Ratio was 36.00. The lowest was 0.00. And the median was 28.32.

Trinity Biotech's EPS (Diluted) for the six months ended in Dec. 2025 was $-1.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.

As of today (2026-06-25), Trinity Biotech's share price is $0.349. Trinity Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.55. Therefore, Trinity Biotech's PE Ratio without NRI ratio for today is At Loss.

During the past 13 years, Trinity Biotech's highest PE Ratio without NRI was 130.91. The lowest was 0.00. And the median was 22.98.

Trinity Biotech's EPS without NRI for the six months ended in Dec. 2025 was $-0.83. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.55.

During the past 3 years, the average EPS without NRI Growth Rate was 27.00% per year.

During the past 13 years, Trinity Biotech's highest 3-Year average EPS without NRI Growth Rate was 43.40% per year. The lowest was -57.80% per year. And the median was -8.00% per year.

Trinity Biotech's EPS (Basic) for the six months ended in Dec. 2025 was $-1.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.

Back to Basics: PE Ratio


Trinity Biotech  (NAS:TRIB) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Trinity Biotech PE Ratio Related Terms


Trinity Biotech PE Ratio Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech PE Ratio Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.75 At Loss At Loss At Loss At Loss

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

TRIB vs PMI, NXL, CSDX: PE Ratio Comparison

For the Medical Devices subindustry, Trinity Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's PE Ratio falls into.


TRIB
20GF Score
Trinity Biotech PLC TRIB
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Trinity Biotech's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.349/-2.000
=-0.17(At Loss)

Trinity Biotech's Share Price of today is $0.349.
For company reported semi-annually, Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.35 is trading 52.2% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • PE Ratio: At Loss
  • GF Value™: $0.73 vs. price of $0.35 (52.2% below fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score

Get the complete analysis for TRIB

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.73
GF Value